| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSAP |
| Uniprot No | P07602 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-524aa |
| 氨基酸序列 | ASGPVLGLKE CTRGSAVWCQ NVKTASDCGA VKHCLQTVWN KPTVKSLPCD ICKDVVTAAG DMLKDNATEE EILVYLEKTC DWLPKPNMSA SCKEIVDSYL PVILDIIKGE MSRPGEVCSA LNLCESLQKH LAELNHQKQL ESNKIPELDM TEVVAPFMAN IPLLLYPQDG PRSKPQPKDN GDVCQDCIQM VTDIQTAVRT NSTFVQALVE HVKEECDRLG PGMADICKNY ISQYSEIAIQ MMMHMQPKEI CALVGFCDEV KEMPMQTLVP AKVASKNVIP ALELVEPIKK HEVPAKSDVY CEVCEFLVKE VTKLIDNNKT EKEILDAFDK MCSKLPKSLS EECQEVVDTY GSSILSILLE EVSPELVCSM LHLCSGTRLP ALTVHVTQPK DGGFCEVCKK LVGYLDRNLE KNSTKQEILA ALEKGCSFLP DPYQKQCDQF VAEYEPVLIE ILVEVMDPSF VCLKIGACPS AHKPLLGTEK CIWGPSYWCQ NTETAAQCNA VEHCKRHVWN KLHHHHHH |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSAP(Prosaposin)重组蛋白的3篇参考文献示例(注：文献为虚构示例，仅作格式参考)：
---
1. **文献名称**: "Recombinant Prosaposin: Production and Neuroprotective Effects in a Mouse Model of Parkinson's Disease"
**作者**: Smith, J. et al.
**摘要**: 研究报道了在大肠杆菌中高效表达并纯化重组PSAP蛋白的方法，并证明其通过激活溶酶体功能减轻帕金森病模型小鼠的神经退行性病变，提示其在神经疾病治疗中的潜力。
2. **文献名称**: "Structural Insights into the Functional Domains of Recombinant Human Prosaposin"
**作者**: Tanaka, K. et al.
**摘要**: 通过X射线晶体学解析了重组人PSAP的分子结构，揭示了其四个同源结构域与鞘脂水解酶结合的分子机制，为设计靶向溶酶体贮积症的突变体提供依据。
3. **文献名称**: "Therapeutic Efficacy of Recombinant PSAP in a Zebrafish Model of Gaucher Disease"
**作者**: Lee, H. et al.
**摘要**: 利用斑马鱼模型评估重组PSAP对戈谢病的治疗效果，结果显示其通过促进葡糖脑苷脂酶的活性显著减少脂质沉积，验证了其作为酶替代疗法的可行性。
---
如需真实文献，建议通过PubMed或Web of Science检索关键词“recombinant prosaposin”或“PSAP expression”。
**Background of PSAP Recombinant Protein**
Prosaposin (PSAP), a highly conserved glycoprotein, serves as a precursor for saposins A-D, which are small lysosomal activator proteins critical for lipid metabolism and lysosomal enzyme function. PSAP is synthesized as a single-chain protein that undergoes proteolytic processing in lysosomes to generate saposins. These peptides facilitate the hydrolysis of sphingolipids by activating specific enzymes, such as β-galactocerebrosidase and glucocerebrosidase, thereby maintaining cellular lipid homeostasis. Beyond its lysosomal role, full-length PSAP exhibits extracellular signaling functions, influencing cell survival, neurogenesis, and inflammation through interactions with G protein-coupled receptors.
Recombinant PSAP protein is engineered using expression systems like mammalian cells or *E. coli* to produce the full-length or saposin-domains. This allows researchers to study its dual intracellular and extracellular roles. Recombinant technology ensures high purity and scalability, enabling applications in disease modeling, drug discovery, and therapeutic development. For instance, PSAP has been explored in lysosomal storage disorders (e.g., Gaucher disease), neurodegenerative conditions (e.g., Parkinson’s), and nerve regeneration due to its neurotrophic properties.
Studies highlight recombinant PSAP’s potential in gene therapy and protein replacement strategies. Its ability to cross the blood-brain barrier enhances its utility in treating central nervous system pathologies. Ongoing research also investigates PSAP’s immunomodulatory effects in cancer and autoimmune diseases. By leveraging recombinant PSAP, scientists aim to address unmet medical needs linked to lysosomal dysfunction and tissue repair, underscoring its multifaceted therapeutic promise.
×
